Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. 1996

F Silvestri, and C Pipan, and G Barillari, and F Zaja, and R Fanin, and L Infanti, and D Russo, and E Falasca, and G A Botta, and M Baccarani
Department of Medical and Morphological Research, University of Udine School of Medicine, Italy.

It has been recently hypothesized that the hepatitis C virus (HCV) might be involved in the pathogenesis of malignant B-cell non-Hodgkin's lymphomas (NHL). On the basis of this observation we sought to determine the prevalence of HCV infection in the patients affected by B-cell NHL and extended our analysis to all the patients affected by lymphoproliferation disorders seen at our institution in the last 30 months. Five hundred and thirty-seven unselected, consecutive patients were studied. HCV infection was investigated through detection of anti-HCV antibodies and HCV-RNA. HCV genotyping was performed on HCV-RNA positive specimens. The risk of being infected by HCV was compared with that of the general population of our area. Among all lymphoproliferative disorders, the prevalence and the relative risk (RR) of being infected by HCV were increased only among B-cell NHL (9%; RR 3.24; p < .0001). Among these, a strong prevalence of HCV was found only in the subgroup of immunocytomas (30%; RR 10.27; P < .0001), while other histotypes were associated with it only occasionally. Because HCV-positive lymphomas clinically behave as essential mixed cryoglobulinemia (EMC), the close association between HCV infection and EMC is confirmed, and evidence is provided that the pathological substrate of EMC corresponds to the immunocytoma. HCV genomic sequences were found in 84% of patients analyzed. Viral genotypes were those more frequent in our area.

UI MeSH Term Description Entries
D007558 Italy A country in southern Europe, a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. The capital is Rome. Sardinia
D008232 Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified. Duncan's Syndrome,X-Linked Lymphoproliferative Syndrome,Duncan Disease,Epstein-Barr Virus Infection, Familial Fatal,Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males,Familial Fatal Epstein-Barr Infection,Immunodeficiency 5,Immunodeficiency, X-Linked Progressive Combined Variable,Lymphoproliferative Disease, X-Linked,Lymphoproliferative Syndrome, X-Linked, 1,Purtilo Syndrome,X-Linked Lymphoproliferative Disease,X-Linked Lymphoproliferative Disorder,Disease, Duncan,Disease, X-Linked Lymphoproliferative,Diseases, X-Linked Lymphoproliferative,Disorder, Lymphoproliferative,Disorder, X-Linked Lymphoproliferative,Disorders, Lymphoproliferative,Disorders, X-Linked Lymphoproliferative,Epstein Barr Virus Induced Lymphoproliferative Disease In Males,Epstein Barr Virus Infection, Familial Fatal,Familial Fatal Epstein Barr Infection,Immunodeficiency 5s,Immunodeficiency, X Linked Progressive Combined Variable,Lymphoproliferative Disease, X Linked,Lymphoproliferative Diseases, X-Linked,Lymphoproliferative Disorder,Lymphoproliferative Disorder, X-Linked,Lymphoproliferative Disorders, X-Linked,Lymphoproliferative Syndrome, X-Linked,Lymphoproliferative Syndromes, X-Linked,Purtilo Syndromes,Syndrome, Purtilo,Syndrome, X-Linked Lymphoproliferative,Syndromes, Purtilo,Syndromes, X-Linked Lymphoproliferative,X Linked Lymphoproliferative Disease,X Linked Lymphoproliferative Disorder,X Linked Lymphoproliferative Syndrome,X-Linked Lymphoproliferative Diseases,X-Linked Lymphoproliferative Disorders,X-Linked Lymphoproliferative Syndromes
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D005260 Female Females
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F Silvestri, and C Pipan, and G Barillari, and F Zaja, and R Fanin, and L Infanti, and D Russo, and E Falasca, and G A Botta, and M Baccarani
January 2002, The Israel Medical Association journal : IMAJ,
F Silvestri, and C Pipan, and G Barillari, and F Zaja, and R Fanin, and L Infanti, and D Russo, and E Falasca, and G A Botta, and M Baccarani
February 2013, Journal of medical virology,
F Silvestri, and C Pipan, and G Barillari, and F Zaja, and R Fanin, and L Infanti, and D Russo, and E Falasca, and G A Botta, and M Baccarani
March 1996, British journal of haematology,
F Silvestri, and C Pipan, and G Barillari, and F Zaja, and R Fanin, and L Infanti, and D Russo, and E Falasca, and G A Botta, and M Baccarani
July 1999, British journal of cancer,
F Silvestri, and C Pipan, and G Barillari, and F Zaja, and R Fanin, and L Infanti, and D Russo, and E Falasca, and G A Botta, and M Baccarani
October 1998, Haematologica,
F Silvestri, and C Pipan, and G Barillari, and F Zaja, and R Fanin, and L Infanti, and D Russo, and E Falasca, and G A Botta, and M Baccarani
June 2014, Journal of viral hepatitis,
F Silvestri, and C Pipan, and G Barillari, and F Zaja, and R Fanin, and L Infanti, and D Russo, and E Falasca, and G A Botta, and M Baccarani
April 2004, JPMA. The Journal of the Pakistan Medical Association,
F Silvestri, and C Pipan, and G Barillari, and F Zaja, and R Fanin, and L Infanti, and D Russo, and E Falasca, and G A Botta, and M Baccarani
January 2020, International journal of immunopathology and pharmacology,
F Silvestri, and C Pipan, and G Barillari, and F Zaja, and R Fanin, and L Infanti, and D Russo, and E Falasca, and G A Botta, and M Baccarani
October 2002, Leukemia,
F Silvestri, and C Pipan, and G Barillari, and F Zaja, and R Fanin, and L Infanti, and D Russo, and E Falasca, and G A Botta, and M Baccarani
November 2007, American journal of hematology,
Copied contents to your clipboard!